In 2016, WHO included JAK2, CALR and MPL mutations in the main diagnostic criteria of MPN and recommended the detection of gene mutations such as TET2, ASXL1, EZH2 and SRSF2 for triple-negative MPNs [2]. Here, JAK2 is linked to myeloproliferative disorder.